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INTRODUCTION
Toll-like receptors (TLRs) that are expressed
mainly on macrophages and dendritic cells (DCs),
are recently identified receptor molecules that rec-
ognize many types of pathogens in addition to
host-derived proteins. Macrophages and DCs are
not only primarily involved in innate immunity, but
are also essential for establishment of adaptive im-
munity as antigen-presenting cells (APCs). Thus,
TLR signaling promotes activation of an innate im-
mune response, and then triggers antigen-specific
adaptive immunity (1-4). In the immunotherapy
against malignant diseases, it was suggested that
the induction of tumor antigen-specific cytotoxic T
lymphocytes (CTLs) is most important for elimi-
nating tumor cells, and most immuno-oncologists
have discussed how to induce adaptive immunity
against cancer. However, the precedent activation
of the innate immune system is essential for the
subsequent induction of antigen-specific immunity.
TLR-mediated activation of innate immunity should
be important for the establishment of an effective
anti-cancer immune response. Recently, several studies
proposed the significance of TLR signaling in the
induction of anti-cancer immunity. In this review,
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we present the recent progress of these studies
including our investigation, focused on the involve-
ment of TLR signaling in anti-cancer immunity.
TLRs, and their ligands
The toll gene controls dorsoventral pattern for-
mation during the early embryonic development of
Drosophila melanogaster (5). Interestingly, toll par-
ticipates in anti-microbial immune responses upon
infection in adult Drosophila (6). Recently, several
mammalian homologues of the Drosophila Toll re-
ceptor protein (Toll-like receptors : TLRs) were iden-
tified. TLRs are transmembrane proteins and rep-
resent a newly recognized family of vertebrate pat-
tern recognition receptors in the innate immune
system. A prerequisite for the development of an
effective host defense is the recognition of patho-
gens. TLRs are involved in this first step (2-4).
Eleven members of the TLR family (TLR1 to TLR10
and RP105)(7-12), co-factors (CD14, MD-1 and
MD-2)(13-15) and their ligands have been reported
(12, 16-46) as shown in Table 1. The well-characterized
TLRs are TLR2, TLR4 and TLR9. TLR4 recognizes
Gram-negative bacteria-derived lipopolysaccharide
(LPS)(32-34) as well as Gram-positive bacteria-derived
lipoteichoic acid (LTA)(17, 35). It was also reported
that TLR 4 mediates LPS-mimetic signal transduction
by an anti-cancer agent Taxol, a plant-derived diterpene,
in mice but not in humans (36). In addition, TLR4
recognizes host-derived proteins, heat shock pro-
tein (HSP) 60 (38, 39) and fibronectin fragment
(40). In the antigen recognition by TLR4, MD-2
plays an essential role. MD-2 is physically associ-
ated with TLR4 on the cell surface and the TLR4/MD-2
complex confers responsiveness to bacterial compo-
nents (15). TLR 2 recognizes peptidoglycan (PGN)
(17, 18), lipoprotein (19-24) and lipoarabinomannan
(LAM)(25, 26) derived from Gram-positive bacte-
ria, mycobacteria or mycoplasma. Several studies
reported that Gram-positive bacteria-derived LTA
is recognized by TLR2 (27-29). TLR9 recognizes
bacterial unmethylated CpG DNA and is the recep-
tor that distinguishes bacterial DNA from self-DNA
(46).
Subsequent to pathogen-associated molecular
pattern engagement, TLRs initiate the signaling
via sequential recruitment of myeloid differentia-
tion protein (MyD) 88, IL-1R-associated kinase (IRAK)
Table 1. TLRs and their ligands
TLRs cofactors ligands origin refs.
TLR1 (associated with TLR2)
TLR2
TLR3
TLR4
TLR5
TLR6 (associated with TLR2)
TLR7
TLR8
TLR9
TLR10
RP105
CD14
CD14
MD-2
MD-1
Soluble factors
PGN
Lipoprotein
LAM
LTA
Zymosan
dsRNA
LPS
LTA
Taxol
F protein
HSP60
Fibronectin EDA
Flagellin
MALP-2
Modulin
Imidazoquinoline
Imidazoquinoline
Unmethylated
CpG-DNA
LPS
Neisseria meningitides
Gram(+),Mycobacteria ,
Gram(+),Mycoplasma
Mycobacteria, Spirochetes
Mycobacteria, Spirochetes
Gram(+)
Yeast
Virus
Gram(-)(E.coli)
Gram(+)
Plant
RSV
Host
Host
Bacteria with flagella
Mycoplasma
Staphylococcus
(Synthetic compound)
(Synthetic compound)
Bacteria
Gram(-)
16
17,18
19-24
25,26
27-29
20,30
31
32-34
17,35
36
37
38,39
40
41
17,42
43
44,45
45
46
12
PGN:peptidoglycan, LAM : lipoarabinomannan, LPS : lipopolysaccharide, LTA : lipoteichoic acid, ds : double-stranded,
RSV : respiratory syncytical virus, HSP : heat shock protein, EDA : extra domain A, MALP-2 : mycoplasmal macrophage-activating
lipopeptide-2 kDa
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and TNFR-associated factor (TRAF)6, which in turn
activate downstream mediators such as nuclear
factor (NF)-κB and mitogen-activated protein
kinases (MAPKs) (47, 48). In addition, experiments
using MyD88-deficient (MyD88-/-) mice revealed that
TLR4 mediates the signaling in an MyD88-independent
fashion in addition to an MyD88-dependent fash-
ion (49). Recently, it was reported that newly iden-
tified molecule, Toll-interleukin 1 receptor (TIR)
domain-containing adapter protein (TIRAP), asso-
ciates with TLR4, and manages MyD88-independent
signal transduction (2, 50). On the other hand, Kawai
et al. reported that a transcription factor, interfer-
on (IFN)-regulatory factor (IRF) 3, translocated into
the nucleus in response to LPS in MyD88-/-mice
(51). It was strongly suggested that IRF3 activation
contributes to the MyD88-independent pathway.
However, it remains uncertain whether TIRAP is
involved in IRF3 activation (Fig. 1). Furthermore,
most recent studies have demonstrated findings
strongly suggesting that TIRAP mediates the sig-
naling via TLR1, TLR2 and TLR6 in addition to TLR4,
and is involved not only in the MyD88-independent
but also in the MyD88-dependent signaling path-
way (52, 53). The downstream molecular events of
TLRs are significant to determine what type(s) of
host response(s) are induced against different kinds
of, and different doses of pathogens. Progress of
this clarification is strongly expected.
TLR-mediated signaling stimulates the maturation
Fig. 1. Ligands with anti-cancer effects and downstream signals of TLRs
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of DCs, which migrate to the regional lymph nodes,
where they stimulate T cells by presentation of
antigen-major histocompatibility (MHC) complex in
addition to costimulatory molecules such as CD80
and CD86. TLR signaling acts to trigger adaptive
immunity by enhancing expression of MHC molecules
in addition to these costimulatory molecules. Further-
more, TLR signaling frequently enhances the pro-
duction of IL-12, a major helper-T cell 1 (Th1)-inducing
cytokine, on APCs (2-4, 54). Thus, it was strongly
suggested that the DCs matured by TLR stimula-
tion may induce T-cell differentiation toward Th1
by presenting antigens to the T cells while promot-
ing a Th 1-leading situation in the local environment.
Therefore, it is possible that the ligands of TLRs
are able to be effective immunoadjuvants for can-
cer therapy. In the next sections, we review the re-
cent progress focused on the TLR ligands as appli-
cations for cancer therapy.
Involvement of TLR2, TLR4, and TLR9 in
anti-cancer immunity induced by the bacillus
´Calmette-Guerin cell wall skeleton (BCG-CWS)
or unmethylated CpG-DNA
1) BCG-CWS-induced anti-cancer host response
via TLR2 and TLR4
Heat-killed mycobacterial cells suspended in min-
eral oil are potent immunoadjuvants to induce both
cell-mediated and humoral immunity, and the CWS
fraction of the cells of mycobacteria is the active
immunoadjuvant component (55-58). It was reported
that BCG-CWS enhances the cytotoxic activity of
T cells and macrophages against cancer cells, and
elicits an anti-tumor effect in mice and in rats bear-
ing transplantable and authochthonous tumors
(59, 60). Further, clinical trials with BCG-CWS were
performed in patients with several types of malig-
nancies, and it was demonstrated that BCG-CWS
was effective in prolongation of survival of patients
especially those with gastric cancer and lung can-
cer (61-67).
Recently, Seya and his co-investigators reported
findings strongly suggesting that BCG-CWS aug-
ments the anti-cancer host response through TLR2
and TLR4 (Fig. 1). It was reported that BCG-CWS
activates and matures DCs (58). Tsuji et al. reported
that BCG-CWS induces tumor necrosis factor (TNF)-α
secretion from DCs via both TLR2 and TLR4, and
that the secreted TNF-α induces the maturation of
DCs (68). The distribution profile of TLR2 and
TLR4 matches the response profile of cells for
BCG-CWS, and further investigation by Tsuji et al.
suggested that the PGN portion of BCG-CWS is
an active center for cytokine induction and DC ma-
turation via Toll signaling (58). It was also reported that
TLR2 mediates mycobacteria-induced proinflammatory
signaling in macrophages (25). These findings strong-
ly suggest that the signaling via TLRs is closely
involved in BCG-CWS-induced anti-tumor immunity.
However, Azuma and Seya suggested that TLRs
are not merely the receptor for establishment of
the BCG-CWS-induced anti-tumor host response,
and proposed the “two receptor theory”. Two types
of receptors expressing on APCs, which consist of
signal transducing receptor related to maturation and
activation of APCs such as TLRs, and phagocytosis-related
receptor to induce antigen presentation to T cells, may
be essential for the establishment of antigen-specific,
adaptive immunity, and BCG-CWS may augment
the anti-tumor host response by activating both types
of receptors (58, 69). As demonstrated previously,
BCG-CWS consists of mycolic acid, arabinogalactan
and PGN (57, 59, 70), and distinct portions may
play significant roles in the binding and activation
of the two receptors on macrophages and DCs.
Identification of the phagocytosis receptor(s) is
currently under investigation by Seya et al. (58).
2) Bacterial unmethylated CpG-DNA-induced host
response via TLR9
The specific immunostimulatory effect of bacte-
rial genomic DNA was first reported by Tokunaga
et al., who demonstrated that bacterial DNA acti-
vates natural killer (NK) cells and induces IFN pro-
duction in addition to tumor regression in some
mouse models, but vertebrate DNA does not (71-
73). In 1995, Krieg et al. demonstrated that CpG mo-
tifs in bacterial DNA trigger direct B-cell activa-
tion (74, 75). They also reported that CpG content
and methylation distinguish vertebrate and bacte-
rial DNAs. Genomic DNA from vertebrates but not
from bacteria contains very few CpG dinucleotide
motifs (76). Further, CpGs are commonly methyl-
ated in vertebrates, while the CpGs are not meth-
ylated in bacteria and viruses. This suggestes the
possibility that the immune system may have evolved
a defense mechanism based on the recognition of
unmethylated CpG-DNAs, which could be a sign of
foreign DNA (76).
The immune response of synthesized oligodeoxynucleotides
(ODN) with CpG motifs was examined. Many studies
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demonstrated that unmethylated CpG-ODN strong-
ly activates immunocompetent cells such as DCs,
macrophages, NK cells, T cells, and B cells, and in-
duces the Th1-like T-cell response including IFN-γ
production and CTL induction, in in vitro and in vivo
models (74). Roman et al. reported that co-injection
of CpG-ODN with a protein antigen greatly enhances
the T- and B-cell response to this antigen (77). Sig-
nificantly, this response is strongly biased toward
the generation of a Th1-dependent immunity with
all its ramifications, for example a preference for
IgG2 immunoglobulin subclasses. It can be expect-
ed as an immunotherapeutic agent for cancer, aller-
gy and infectious diseases as a potent Th1 induc-
er. The efficacy of CpG-DNA in preventing or treat-
ing tumor development or metastasis in mice has
been examined in several experimental models. In
CpG-DNA monotherapy, systemic or local admini-
stration of CpG-DNA protected 80% of syngeneic
C57BL/6 mice from a lethal challenge of B16 mela-
noma. Further, SCID mice were also protected against
tumor challenge by CpG-DNA, which suggests that
neither B nor T cells are required (78). The poten-
tial of the CpG-DNA as an adjuvant for cancer vac-
cines was also examined. CpG-DNA-induced activa-
tion of DCs creates a Th1-like cytokine and chemokine
environment in the secondary lymphoid organs that
promotes cross-priming with strong IFN-γ-secreting
CTLs and antibody responses to peptides and pro-
tein antigens derived from tumors, and elicits marked
anti-tumor activity (79, 80). Despite its promising
clinical use, the molecular mechanism by which
CpG-DNA activates immune cells has remained
unclear.
In 2000, Hemmi et al. discovered the receptor mol-
ecule recognizing bacterial DNA (46). The identi-
fied protein, TLR9, recognizes the unmethylated CpG
motif in bacterial DNA, and mediates an innate im-
mune response (Fig. 1). They generated TLR9-deficient
(TLR9-/-) mice and examined the immune effect
of CpG-ODN using those mice (46). TLR9-/- mice
did not show any response to CpG-DNA, including
proliferation of splenocytes, inflammatory cytokine
production from macrophages and maturation of
DCs. TLR9-/-mice showed resistance to the lethal
effect of CpG DNA without any elevation of serum
pro-inflammatory cytokine levels. The in vivo
CpG-DNA-mediated Th1 response was also abol-
ished in TLR9-/-mice. Thus, it was clarified that
the signaling via TLR9 plays an important role in
CpG-DNA-induced host response.
Early-stage clinical trials of CpG-DNA as an
immunotherapeutic agent for cancers and as an
anti-allergic agent are currently on going, and pre-
liminary findings from these trials appear to be en-
couraging (81).
Involvement of TLR4/MD-2 signaling in anti-cancer
immunity induced by an LTA-related mol-
ecule, an effective component of OK-432,
or by a plant-derived 55-kDa protein
Recently, we obtained 2 molecules that can induce
the Th1-dominant state and elicit an anti-cancer ef-
fect. One is an LTA-related molecule isolated from
a Streptococcus-derived anti-cancer agent OK-432,
and another is a 55-kDa protein from Aeginetia indica
L (AIL), a parasitic plant, and we obtained findings
strongly suggesting that these molecules enhance
anti-cancer immunity via TLR4/MD-2 complex. In
this section, we present the recent progress of our
basic and translational research focused on the in-
volvement of TLR4/MD-2 signaling in anti-cancer
immunity induced by these molecules.
1) Isolation of an effective component responsible
for OK-432-induced anti-cancer effect
OK-432, a penicillin-killed and lyophilized prepa-
ration of a low-virulence strain (Su) of Streptococcus
pyogenes (group A) (Chugai Pharmaceutical Co., Ltd.,
Tokyo, Japan), was developed by Okamoto et al. in
1967 (82), and has been successfully used as an
immunotherapeutic agent in many types of malig-
nancies (83-87). We also reported that OK-432-based
immunotherapy exhibits a marked therapeutic ef-
fect in patients with oral squamous cell carcinoma
(88, 89). Previous studies helped to clarify the cel-
lular mechanism of OK-432-induced anti-cancer im-
munity. Namely, OK-432 elicits anti-tumor effects
by stimulating immunocompetent cells such as
macrophages, T cells and NK cells, and by induc-
ing multiple cytokines including IL-1, IL-2, IL-6,
TNF-α, and IFN-γ (90-92). In addition, OK-432 in-
duces IL-12 and polarizes the T-cell response to a
Th1 dominant state (93). However, there has been
limited progress in elucidating the molecular mecha-
nism, i.e., in the identification of the effective mol-
ecule(s) for inducing anti-cancer immunity in whole
bacterial preparation OK-432 and their molecular
target(s), such as receptors and signal transducers
on immunocompetent cells. Recently, we succeed-
ed in isolating the LTA-related molecule that is
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most responsible for the anti-cancer effect of OK-432.
This molecule designated as OK-PSA was isolated
from a butanol extract of OK-432 using a CNBr-activated
Sepharose 4B affinity column bound with the monoclonal
antibody TS-2, which neutralizes the IFN-γ-inducing
activity of OK-432 (94, 95). We previously reported
that OK-PSA is a more potent inducer of Th1 cytokines
and killer cell activities on human peripheral blood
mononuclear cells (PBMCs) than original OK-432,
and showed a marked anti-tumor activity in tumor-bearing
mice (94, 96-101)
2) OK-PSA-induced anti-cancer immunity via TLR4
signaling
We examined the role of TLR4 in the anti-tumor
effect of OK-PSA using C3H/HeJ mice in which
TLR4 is mutated and its function is impaired (34).
C3H/HeN mice, which have the wild-type TLR4
gene, were used as control animals. In in vitro ex-
periments, the spleen cells derived from C3H/HeN
and C3H/HeJ mice were stimulated with OK-PSA
for 48 h, then the cytokines in the supernatants were
measured. Although Th1-type cytokines such as
IFN-γ, IL-12 and IL-18 were significantly induced
by OK-PSA stimulation in the splenocytes derived
from C3H/HeN mice, these cytokines were not in-
duced in the splenocytes from C3H/HeJ (Fig. 2A).
TNF-α and IL-2 were also induced by OK-PSA in
the splenocytes from C3H/HeN but not from C3H/HeJ
(data not shown). Furthermore, when the expres-
sion vector including mouse TLR4 cDNA was transfected
into C3H/HeJ-derived splenocytes, the splenocytes
acquired the responsiveness to OK-PSA to produce
Th1 cytokines (Fig. 2B). Next, we evaluated the
anti-tumor effect of OK-PSA in vivo . C3H/HeN and
C3H/HeJ mice bearing syngeneic SCCVII tumors
were treated with OK-PSA. The peritumoral injec-
tion of OK-PSA resulted in significant inhibition of
tumor growth and lung metastasis in SCCVII-bearing
C3H/HeN mice ; however, no effect of OK-PSA
was observed in C 3 H/HeJ mice (Fig. 2 C). The cytolytic
activities of tumor-infiltrating lymphocytes (TIL) and
draining lymph node (LN) cells derived from SCCVII-bearing
mice that were administered OK-PSA were also
analyzed. The cytolytic activities of TIL and LN
cells against SCCVII were markedly increased by
OK-PSA administration in C3H/HeN but not in
C3H/HeJ (Fig. 2D). These findings strongly sug-
gest that TLR4 signaling is involved in regulating
OK-PSA-induced anti-cancer immunity (102, 103). As de-
scribed above, several studies reported that Gram-
positive bacteria-derived LTA is recognized by TLR2
(27-29). Recent studies by Hartung et al. have dem-
onstrated that the butanol-extracted LTA in addi-
tion to synthetic LTA from Staphylococcus aureus
induce cytokines through TLR2 but not through
TLR4 (28, 29). Further, it was also reported that
LTA from Bacillus subtilis and from Staphylococcus
aureus induced the maturation of murine DCs via
TLR4 (27). Since TS-2 mAb recognizes LTAs similar
to OK-PSA, it is suggested that OK-PSA has a cer-
tain chemical structure that LTAs share in common
(94, 95), while the active structure of OK-PSA may
not be LTA itself. Furthermore, recent evidence in
LPS recognition suggests that there are structural
and functional differences among LPS molecules
from different bacteria. An LPS with a conical shape
(e.g. from Escherichia coli) induces cytokines via
TLR4, while a more cylindrical LPS (e.g. from
Porphyromonas gingivalis) induces a different set
of cytokines via TLR2 (104). It is possible that
OK-PSA, a ligand for TLR4, may be a member of
the LTA family with a different structure.
3) OK-PSA-induced DC maturation via TLR4 sig-
naling
To evaluate the role of TLR4 in OK-PSA-induced
maturation of human DCs, we performed a neutralizing
test using anti-human TLR4 mAb (HTA 125, 10 µg/ml ;
provided from Drs. Miyake and Akashi, The Insti-
tute of Medical Science, The University of Tokyo).
When monocyte-derived immature DCs (iDCs) from
healthy donors were stimulated by OK-PSA for 48 h,
the increased expression of surface markers such
as MHC class II, CD80 and CD86, and enhancement
of the production of IL-12 and IL-18 were observed.
The expression of these markers increased by OK-PSA
was almost completely inhibited by the addition of
anti-human TLR4 mAb. OK-PSA-induced cytokine
production was also inhibited significantly by anti-TLR4
(Table 2). We next used the monocyte-derived iDCs
from patients with oral cancer. In semiquantitative
RT-PCR analysis, TLR4 mRNA was strongly expressed
in peripheral blood monocytes both from patient 1
and from patient 2. MD-2 mRNA was clearly de-
tected in patient 1-derived monocytes, while it was
not detected in those from patient 2 in the current
RT-PCR condition (data not shown). OK-PSA stimu-
lation increased the expression of MHC class II,
CD80 and CD86 on iDCs derived from patient 1.
The expression of these cell surface antigens was
also increased by OK-PSA on patient 2-derived DCs.
Although DCs derived both from patient 1 and
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from patient 2 produced IL-12 by OK-PSA treat-
ment, IL-12 secretion by patient 1-derived DCs was
greater than that by patient 2-derived DCs. Next,
these OK-PSA-treated or untreated DCs were irra-
diated, then cocultured with allogeneic T cells (DC :
T=1 : 20) for 5 days. IFN-γ in the supernatants from
the cocultivation was markedly increased when T
cells were cocultured with patient 1-derived DCs
treated with OK-PSA compared with patient 2-derived
DCs. Futher, allo-specific CTL activity of the T cells
harvested from the above culture was also exam-
ined. CTL activity was significantly increased only
when the T cells were cocultured with patient 1-derived
DCs activated by OK-PSA but not with DCs from
patient 2 (Table 2) (Okamoto and Sato, manuscript
in preparation).
4) Requirement of both TLR4 and MD-2 genes in
IFN-γ induction by OK-432 administration in oral
cancer patients
We evaluated the relation between the expression
Fig. 2. OK-PSA-induced anti-cancer host response via TLR4. (A) Cytokine production by OK-PSA-stimulated splenocytes derived
from C 3 H/HeN and C3H/HeJ. The splenocytes (2×106/ml) were stimulated with OK-PSA, OK-432 or LPS for 48 h, then cytokines
in the supernatants were measured. ＊, P <0.01 ; #, P <0.05 compared with C3H/HeN mice. (B) Effect of transfection of TLR4 gene in
the response of C3H/HeJ-derived splenocytes against OK-PSA. C3H/HeJ-derived splenocytes (3.5×106) were transiently transfected
with the expression plasmid containing mouse TLR4. Twenty-four hours later, the splenocytes were treated with 1 µg/ml of OK-
PSA, OK-432 or LPS for 48 h, and then cytokines in the supernatants were measured. ＊, P <0.01 ; #, P <0.05 compared with the
controls. (C) Inhibition of tumor growth and lung metastasis by OK-PSA in C3H/HeN and C3H/HeJ. SCCVII-bearing C3H/HeN
(n=10) and C3H/HeJ (n=10) were administered with OK-PSA (100 µg) peritumorally every other day from days 1 though 9 after the
inoculation of SCCVII. ＊, P<0.001 compared with the control animals administered saline. (D) Cytotoxic activities of tumor
infiltrating lymphocytes (TIL) and draining lymph node (LN) cells. SCCVII-bearing C3H/HeN and C3H/HeJ treated with OK-PSA
were killed on day 23, and were analyzed for the cytotoxic activities of TIL and LN cells against SCCVII. ＊, P <0.01 ; #, P <0.05
compared with controls administered saline.
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of TLR4 and MD-2 genes and IFN-γ induction in
response to OK-432 in 28 oral cancer patients. Nine-
teen of 20 patients (95%) who showed TLR4(+)
and MD-2(+), demonstrated an increase in serum
IFN-γ protein by peritumoral administration of OK-432.
Serum IFN-γ protein was not detected after OK-432
administration in six of eight (75%) patients who
showed TLR4(-) or MD-2(-). We detected a signifi-
cant relation between increased IFN-γ protein levels
in the sera of patients administered OK-432 and
expression of TLR4 and MD-2 genes (P =0.0005 in
Fisher’s exact test, Table 3). Both TLR4 and MD-2
were apparently required for IFN-γ induction by
OK-432 in patients with oral cancer (105). All of the
patients examined in that study received therapy
with OK-432 and UFT, an oral fluoropyrimidine for-
mulation combining tegafur and uracil in a 1 : 4 ra-
tio (Taiho Pharmaceutical Co., Tokyo, Japan) in
combination with radiotherapy. Among these pa-
tients, 10 of 20 TLR4(+)MD-2(+) patients (50%) be-
came histopathologically tumor-free after the thera-
py, and without surgical resection. In contrast, all
eight patients who were TLR 4(-) or MD-2 (-) became
tumor-free only after having their tumors surgical-
ly resected after the therapy (105). We also clarified
the requirement of TLR4 signaling for OK-432-induced
anti-cancer immunity in a mouse model using TLR4-/-
mice (105).
These basic and clinical findings described above
suggest that the target receptor molecule of origi-
nal OK-432 in addition to its component OK-PSA is
TLR4/MD-2 complex, and that the expression of
TLR4 and MD-2 may be a useful marker to discrimi-
nate between responders and nonresponders to
OK-432-based immunotherapy. Furthermore, these
findings strongly support our opinion that the mole-
cule which makes the largest contribution to the
OK-432-induced anti-cancer immunity, is OK-PSA.
Table 2. TLR 4/MD-2-mediated DC maturation by OK-PSA
TLR 4/MD-2-mediated maturation of oral cancer patient-derived DCs by OK-PSA
donors treatment
surface markers
IL -12
(pg/ml)
allogeneic MLR
Class II CD80 CD86 IFN-γ (pg/ml) allo-specific CTL
(% cytotoxicity)
patient 1
TLR4(+)MD-2(+)
patient 2
TLR4(+)MD-2(-)
untreatd
OK-PSA
untreatd
OK-PSA
122
267
76.7
249
2.8
8.3
3.2
6.9
10.7
23.7
7.3
27.1
10.2±1.8
4356±254
15.3±2.5
1872±146＊
75.5±11.3
623±52
101±8.5
289±31＊
17.7±25
42.5±3.3
21.5±3.2
18.2±1.5＊
In patient 1, expression of both TLR4 and MD-2 genes was detected by semi-quantitative RT-PCR analysis. MD-2 mRNA expression
was not detected in patient 2. Cell surface phenotype of patient-derived DCs stimulated by OK-PSA for 2 days was analyzed by flow
cytometry. Numerals in the table express mean fluorescence intensities. IL-12 in the supernatants were measured by ELISA.
Patient-derived DCs stimulated by OK-PSA were cocultured with allogeneic T cells derived from another oral cancer patient (DC :
T=1 : 20) for 5 days, and then the supernatants of the cocultivation were analyzed for IFN-γ by ELISA. The cytotoxic activities of the
T cells harvested from the above allogeneic MLR culture were assayed against antigen-specific target cells, iDCs derived from the
same donor to the DCs used in MLR by a 51Cr-release test. ＊, P <0.01 compared with patient l-derived DCs treated with OK-PSA.
TLR 4-mediated maturation of healthy donor-derived DCs by OK-PSA
surface markers cytokines
Class II CD80 CD86
IL-12
(pg/ml)
IL-18
(pg/ml)
untreatd
OK-PSA
anti-TLR4
OK-PSA
+anti-TLR4
545
2217
524
625
35.8
92.2
33.5
33.9
188
331
205
210
20.0±1.7
3080±65
22.9±0.5
582±22＊
4.2±0.5
116±9.5
3.5±1.2
25.5±1.8＊
Human monocyte-derived iDCs were treated with OK-PSA (10 µg/ml) for 2 days. In some experiments, anti-human TLR4 mAb (10
µg/ml) was added at 2 h before adding OK-PSA. After the completion of the cultivation, expression of surface markers on the DCs
was analyzed by flow cytometry using FITC-conjugated mAb against each marker. Numerals in the table express mean fluores-
cence intensities. IL-12 and IL-18 in the supernatants were also measured by ELISA. *, P <0.01 compared with positive controls
treated with OK-PSA alone.
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5) Isolation of a 55-kDa protein and its anti-tumor
effect via TLR4 signaling
Aeginetia indica L. (AIL), a plant parasitic on roots
of Japanese pampa grasses or sugar canes, has been
used as a tonic and an anti-inflammatory herb agent
in China and Japan. We previously reported that the
butanol extract from seeds of AIL mediates potent
anti-tumor immunity in tumor-bearing mice (106-
108). We recently isolated a 55-kDa protein from
the seed extract of the plant, and designated AILb-A.
We reported that AILb-A was the protein with a
molecular weight of 55-kDa not containing any car-
bohydrate determinants and markedly induced
Th1-type cytokines and apoptosis-inducing factors
such as TNF-α, TNF-β, Fas ligand, TNF-related
apoptosis-inducing ligand (TRAIL) and perforin on
human PBMCs in vitro (108, 109), and that AILb-A
induced Th1-dominant state and elicited marked
anti-tumor effects in syngeneic Meth-A tumor-bearing
BALB/c mice in which the Th2 response is geneti-
cally dominant. It is strongly suggested that AILb-A
may be a useful immunotherapeutic agent for pa-
tients with malignancies (110).
We examined the role of TLR4-mediated signal-
ing in AILb-A-induced anti-tumor immunity. In the
luciferase assay using NF-κB-dependent reporter
plasmid, AILb-A induced NF-κB activation in the
cells transfected with the plasmid containing TLR4
gene in a dose-dependent manner. In the cells transfected
both with TLR4 and with MD-2 genes, higher ac-
tivity of NF-κB was observed by AILb-A stimulation
than that in the cells expressing only TLR4. These
cells transfected with TLR4 and/or MD-2 genes
were provided by Drs. Miyake and Akashi, The In-
stitute of Medical Science, The University of Tokyo.
AILb-A did not induce cytokines (TNF-α and IL-12) in
the peritoneal macrophages derived from TLR4-deficient
mice (provided by Drs. Akira and Takeuchi, Research
Institute for Microbial Diseases, Osaka University), while
cytokines were markedly produced by AILb-A-stimulated
macrophages from wild-type and TLR2-deficient mice
(provided by Drs. Akira and Takeuchi). Further, in
wild-type and TLR2-deficient mice bearing syngeneic
LL/2 tumor, AILb-A treatment resulted in marked
inhibition of tumor growth, but AILb-A was not ef-
fective in LL/2-bearing TLR4-deficient mice (Okamoto
and Sato, manuscript in preparation). These findings
suggest that AILb-A induces anti-cancer immunity
via TLR4 signaling.
DISCUSSION AND FUTURE PERSPEC-
TIVES
Although the major therapies for malignancies
are surgical resection, chemotherapy and radiotherapy,
the accumulated evidence demonstrates that the
host immune response is essential for eliminating
cancer cells completely. Augmentation of anti-cancer
immunity in patients is significant to cure the diseases
in addition to increase the quality of life of patients
with cancer. Recent studies strongly suggest that TLR
ligands are useful applications for immunotherapy
for cancer patients. The schema of TLR ligand-induced
anti-cancer immunity is shown in Fig. 3. In tumor
tissues, bacterial components such as BCG-CWS,
CpG-DNA and OK-PSA, in addition to a plant-derived
protein, AILb-A, activate APCs which have captured
tumor antigens, via TLRs. TLR-mediated signaling
stimulates the maturation of DCs. The matured
DCs in which expression of MHC and costimulatory
Table 3. Requirement of TLR4 and MD-2 in OK-432-induced IFN-γ in sera from oral cancer patients
patient No.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TLR4
MD-2
Serum
IFN-γ
+
-
-
+
+
+
+
+
+
+
+
-
+
+
+
+
+
+
-
+
-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
-
+
-
+
+
+
+
+
+
+
+
+
+
+
+
+
-
+
-
+
+
+
+
-
+
+
-
-
+
+
+
+
-
-
Peripheral blood mononuclear cells were prepared from 28 patients with oral cancer. Total RNA was extracted from the cells, then
expression of TLR4 and MD-2 mRNAs was examined by semi-quantitative RT-PCR analysis. Densitometric analysis for the RT-PCR
band patterns was performed by using NIH Image 1.59 software. The relative density (RD) of each specific band was expressed as
a ratio to the density of GAPDH used as an internal control, and RD<0.1 was defined as -, 0.1≦RD<0.5 as ±, and RD≧0.5 as +. Sera
were collected from these patients at 5 h before and at 24 h after the peritumoral administration of OK-432, then IFN-γ was ana-
lyzed by ELISA. IFN-γ was not detected in the sera collected before OK-432 administration in any patients (data not shown). There-
fore, the case in that IFN-γ protein was detected in the sera collected after OK-432 administration, was expressed +.
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molecules is increased by TLR stimulation, migrate
to the regional lymph nodes, then present antigen(s)
to T cells. TLR-stimulated DCs also enhanced the pro-
ducing ability of cytokines such as IL-12 and IL-18, po-
tential Th1-inducing cytokines. Therefore, TLR-stimulated
DCs may effectively induce tumor-antigen specific
Th1 and CTL by presenting antigens to CD4+ and
CD8+T cells while promoting a Th1-leading situa-
tion. It is possible that some ligands of TLRs are
able to be effective immunotherapeutic agents for
patients with cancer. Based on the results of our
and other studies with regard to the role of TLR
ligands on DC function as described above, TLR
ligands may be useful applications as adjuvants in
DC-based cancer immunotherapy. Clinical trials
are expected.
As described by many investigators and oncologists,
the therapy to increase the host response in cancer
patients should be effective, while it is a critical prob-
lem for clinical use of the immunoadjuvants that the
molecular mechanism by which the immunotherapeuitic
agents activate immune cells, has remained uncer-
tain. Discovery of TLRs as immunoadjuvant recep-
tors is a great progress to use the immunoadjuvants
to treat human cancer. Furthermore, when TLR
ligands are used in therapeutic applications, the
expression of TLRs in the patients may be a useful
marker to discriminate between responders and
nonresponders to the therapy using the agents. For
example, if a patient does not express TLR4/MD-2,
CpG-DNA but not OK-PSA should be selected as a
therapeutic application. CpG-DNA should not work
in patients in whom TLR9 is not expressed. In ad-
dition, stimulation of both TLR4 and TLR9 by the
combination therapy using OK-PSA and CpG-DNA
may be more effective to cure cancers in patients
expressing both TLR4/MD-2 and TLR9.
The residual problem is that all TLR ligands and
all types of signaling mediated by TLRs do not in-
duce the Th1-type T-cell response. The next objective
of these studies is to clarify the Th1-inducing mecha-
nism(s) via TLRs, in addition to find Th1-inducing
ligand(s) of TLRs. Establishment of the methodol-
ogy to specifically induce the Th 1 response by utiliz-
ing TLR signaling is expected for future immunotherapy
against cancers, allergic diseases in addition to in-
fectious diseases. Further, if TLR ligand(s) that can
selectively induce the Th2-type T-cell response will
be found, it may be effective for the treatment of
Th1-associated diseases such as autoimmune dis-
eases.
With regard to our work, both the OK-432-derived
component OK-PSA and plant-derived 55-kDa pro-
tein AILb-A augment anti-cancer immune response
by acting as potent Th1 inducers mediated by
TLR4/MD-2 signaling. In an attempt to apply these
agents for the treatment of human cancers, the
determination of the chemical structure of OK-PSA
Fig. 3. TLR-mediated anti-cancer host response.
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and the isolation of the gene encoding AILb-A should
be completed. It is currently under investigation in
our laboratories. We believe that OK-PSA as well
as AILb-A will be useful immunotherapeutic agents
for patients with malignant diseases.
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